摘要
背景：目前肢端肥大症的治疗方案仍以手术为首选,放疗或药物作为术后辅助治疗的手段。但是手术治疗的成功率不高,尤其对大腺瘤及侵袭性大腺瘤的患者,手术常常并不能完全地切除肿瘤。生长抑素类似物(SSA)治疗能够降低GH水平及缩小肿瘤体积,而术前GH水平以及肿瘤大小是手术效果的预测因子,而因此在术前短期应用SSA治疗在理论上可以提高手术的效果。
目的：利用卫生经济学的成本效果分析手段来评价先短期使用药物(主要是指长效生长抑素类似物)治疗后再行手术治疗(术前用药)和以手术为初始治疗方法(初治手术)这两种治疗方案在治疗肢端肥大症中的治疗效果和成本。
方法：回顾分析了168份符合入选标准的病历,其中20份为术前用药,148份为初治手术,得出两种治疗方案的治疗成功率、手术并发症等数据；并利用马尔科夫(Markov)模型模拟肢端肥大症术后在实际临床中可能出现的三种情况：术后未愈者进行二次手术+放疗、放疗+药物过渡治疗及长期用药(分别简称为二次手术、放疗、长期用药),进而按这三种情况分别评价两种方案的治疗效果及成本。
结果：在治疗微腺瘤方面,两种治疗方案的治疗成功率无统计学的显著差异。而在治疗大腺瘤方面,术前用药的治疗成功率要高于初治手术,术前用药患者的预期寿命和质量调整生命年均高于初治手术治疗,而成本方面,在二次手术组,术前用药高于初治手术,而在放疗组及长期用药组,术前用药低于初治手术。
结论：术前用药这种方案在治疗肢端肥大症大腺瘤方面较初治手术治疗方案具有成本效果优势。
目的：了解肢端肥大症患者的生存质量情况及其影响因素。
方法：横断面调查,利用肢端肥大症生存质量调查量表(ACROQoL)评价患者的生存质量情况。
结果：生化控制组在心理精神的子维度外貌评分高于未控制组(P=0.044),而在其它维度并无显著性差异。而在按有无并发症及放疗划分的亚组中,仅在控制组内,无并发症亚组在人际关系评分高于有并发症亚组。
结论：肢大对患者的生存质量有负面的影响,GH水平影响肢大患者的心理精神子维度外貌评分。
Background Many studies have showed that GH levels at the time of diagnosis and tumor size are predictive of surgical outcomes in patients with acromegly, and therefore, any therapy that decrease GH levels and tumor size before surgery would have a theoretical advantage. We estimated the cost effectiveness of two therapeutic schemes: preoperative medical therapy followed by surgery and surgery as primary therapy.
Methods Retrospective analysis of168cases. We estimated the cost per year of life gained and the cost per quality-adjusted years of life gained with the two therapeutic schemes. To estimate the cost and the effects, Makov models were used.
Results In the patients with macroadenoma, the remission rate of the therapeutic scheme of preoperative medical therapy followed by surgery is higher than that of surgery as primary therapy. We modeled three different treatments after surgery using Makov model, and we found that as for macroadenoma, the cost per year of life gained and the cost per quality-adjusted years of life gained with the therapeutic scheme of preoperative medical therapy followed by surgery are higher than that of the therapeutic scheme of surgery as primary therapy in the subgroup of secondary surgery. However, the cost per year of life gained and the cost per quality-adjusted years of life gained with the therapeutic scheme of preoperative medical therapy followed by surgery are lower than that of the therapeutic scheme of surgery as primary therapy in the subgroup of radiotherapy and drug therapy
Conclusions In acromegalic patients with macroadenoma, the therapeutic scheme of preoperative medical therapy with long acting SSA followed by surgery is cost effective.
Objective:The aim of this study was to evaluate the quality of life(QOL) in patients with treated acromegaly and its influential factors.
Design:cross-sectional study.
Metods:We used the Acromegaly Quality of Life Questionnaire(ACROQoL). to evaluate QOL in patients with treated acromgaly.61patients wre divided into controlled and uncontrolled groups based on the remission criteria and further subdivided into eight groups according to with/without complications or radiotherapy. Comparisons between groups were analyzed.
Results:In comparison with the uncontrolled groups, the controlled groups showed better ACROQoL scores in psychological subscale "appearance"(P=0.044). And in subgroups, only the subgroup of with complications in controlled group was found to have higher scores in psychological subscale "personal relationship" than the subgroup of without complications.
Conclusions:Acromegaly has an important impact on quality of life. The level of GH is negatively associated with psychological subscale "appearance" in patients with acromegaly.
引文
(1)中华医学会内分泌分会中华医学会神经外科分会.中国肢端肥大症诊治规范.中国实用内科杂志.2006,26：1772-1777.
(2)David M. Cook, Shereen Ezzat, Laurence Katznelson, et al. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the diagnosis and treatment of acromegaly. Endocrine practice.2004,10:213-225.
(3)Shlomo Melmed. Acromegaly. NEJM 2006;355:2558-73.
(4)Rocio A. Cordero, Ariel L. Barkan. Current diagnosis of acromegaly. Rev Endocr Meta Disord 2008;9:13-19.
(5)Annamaria Colao, RenSTA S. Auriemma, Rosario Pivonello, et al. Medical consequences of acromegly:What the effects of biochemical control? Rev Endocr Metab Disord.2008;9:21-31.
(6)Dekkers OM, Biermasz NR, Pereira AM, et al. mortality in acromegaly:A metaanalysis. J Clin Endocrinol Metab.2008 Jan;93(1):61-7.
(7)Laurence Katznelson. Current thinking on the management of the acromegalic patient. Current Opinion in Endocrinology, Diabetes&Obesity,2007,14:311-316.
(8)Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab.2004 Feb;89(2):667-74.
(9)Sheppard MC. GH and mortality in acromegaly. J Endocrinol Invest.2005,28(11 Suppl International):75-7.
(10)史轶繁主编协和内分泌和代谢学[M].第一版.北京：科学出版社,1999：674-699.
(11)Edward R. Laws. Surgery for acromegaly:Evolution of the techniques and outcomes. Rev Endocr Metab Disord 20008;9:67-70.
(12)Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical'cure'. Eur J Endocrinol 2005; 152:379-387.
(13)Erdinc Erturk, Ercan T, et al. Outcome of Surgery for Acromegaly Performed by Different Surgeons:Importance of Surgical Experience. Pituitary 2005,8:93-97.
(14)顾锋肢端肥大症的内科治疗新进展.中国实用内科杂志.2006,26(22)：1777-1779.
(15)Zachary. B, Mary. V. Management of acromegaly:Is there a role for primary medical therapy?. Rev Endocr Metab Disord.2008,9:83-94.
(16)G. Didoni, S. Grottoli, et al. cost-of-illness study of acromegaly patients in Italy. J. Endocrinol. Invest.2004,27:1034-1039.
(17)Landolt AM, Haller D, Lomax N, et al. Stereotactic radiosurgery for recurrent surgically treated acromegaly:comparison with fractionated radiotherapy. J Neurosurg 1998; 88:1002-1008.
(18)Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab.2002,87(7):3013-8.
(19)Annamaria Colao, Rosario Pivonello, Francesca Rosato, et al. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly:
(20)Freda PU, Katznelson L, van der Lely AJ,et al. Long-acting somatostatin analog therapy of acromegaly:a meta-analysis. J Clin Endocrinol Metab.2005 Aug;90(8):4465-73.
(21)Colao A, Attanasio R, Pivonello R, et al. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly
(22)Etrossians P, Borges-Martins L, Espinoza C, et al. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol.2005 May,152(5):693-4.
(23)Colao A, Pivonello R, Auriemma RS, et al. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly:a prospective study in 99 patients. J Clin Endocrinol Metab 2006; 91:2112-2118.
(24)Shlomo Melmed, Richard Stemberg, David Cook, et al. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. The Journal of clinical Endocrimodogy &Metabolism.2005;90:4405-4410.
(25)Lucas T, Astorga R, CSTAla M, et al. Preoperative lanreotide treatment for GH-secreting pituitary adenomas:effect on tumour volume and predictive factors of significant tumour shrinkage. Clin Endocrinol (Oxf).2003 Apr;58(4):471-81.
(26)Renato Cozzi, Marcella Montini, Roberto Attanasio, et al. Primary treatment of acromegaly with octereotede Lar:A longterm(up to 9 years) prospective study of its efficacy in the contol jof disease actity and tumor shrinkage. J Clin Edocin Metab.2006; 10:2005-2347.
(27)陈洁主编卫生经济学.第1版.北京：人民卫生出版社,2006：1-8.
(28)胡善联.卫生经济学概述.卫生经济研究1998,11(121)：42-44.
(29)A.J. Culyer, J.P. Newhouse. Handbook of health economics, volume 1:182-219.
(30)Alan M. Garber, Charles E. Phelps. Economic foundations of cost-effectiveness analysis. Journal of Health Economics 16(1997):1-31.
(31)Peter J. Neumann, Allison B. Rosen, Milton C. Weinsteiin. Medicare and cost-effectiveness analysis. N ENG J MED 353; 14:1516-1522.
(32)Knutzen R, Ezzat S. The cost of medical care for the acromegalic patient. Neuroendocrinology. 2006;83(3-4):139-44.
(33)Wilson LS, Shin JL, Ezzat S. Longitudinal assessment of economic burden and clinical outcomes in acromegaly. Endocr Pract.2001,7(3):170-80.
(34)Luque-Ram i rez M, Paramo C, et al. Cost of management of invasive growth hormone-secreting macroadenoma. J Endocrinol Invest.2007,30(7):541-5.
(35)Ingrid B, Ron D, et al. The'bio-assay'quality of life might be a better marker of disease activity in acromegalic patients than serum total IGF-I concentrations. European Journal of Endocrinology. 2005,152:217-224.
(36)Andrew Briggs, Mark Sculpher. An introduction to Markov modeling for economic evaluation Pharmacoeconomics 1998 Apr:13(4):397-409.
(37)Markov models in medical decision making:a practical guide. Frank A. Sonnenberg, LRobert Beck. Medical Decision Making 1993;13:322-339.
(38)Primer on medical decision analysis:part5-Working with markov processes. David Naimark, Murray D Krahn, Gary Naglie. Med Decis Marking 1997; 17:152-159.
(39)SUN Xin. Markov Modelling in Healthcare Economic Evaluations. Chin J Evid-based Med, 2007,7(10):750-756.
(40)巢健茜刘沛何建敏马尔可夫过程在医学干预措施成本效用分析中的应用 《数理统计与管理》2007,26：
(41)孙晓花刘爱忠应用Markov模型进行临床决策分析的思考《医学与哲学》2004,25：8-9.
(42)David Meltzer. Accounting for future costs in medical cost-effectiveness analysis.Journal of Health Economics.1997,16:33-64.
(43)胡善联卫生经济研究1998,121：42-44.
(44)朱善利微观经济学2001年第一版,北京大学出版社。
(45)Evelyn W, et al. Guideline on health economic evaluation (Austria). April 2006.
(46)蒯丽萍,张钧.卫生经济学的成本测算与分析.药学实践杂志2005,23(2)：124-127.
(47)吴久鸿,刘国恩.卫生经济学在我国的发展现状及应用前景.中国药物应用与监测.2005,1：14.
(1)Shlomo Melmed. Acromegaly. NEJM 2006;355:2558-73.
(2)Rocio A. Cordero, Ariel L. Barkan. Current diagnosis of acromegaly. Rev Endocr Meta Disord 2008;9:13-19.
(3)Webb SM. Quality of life in acromegaly Neuroendocrinology.2006;83(3-4):224-9.
(4)Nienke R. Biermasz, Sjoerd W. Thiel, Alberto M. Pereira, et al. Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. The Journal of Clinical Endocrinology & Metabolism.2004,89:5369-5376.
(5)Ritva Kauppinen-Makelin, Timo Sana, Harri Sintonen, et al. Quality of life in treated patients with acromegaly. The Journal of Clinical Endocrinology & Metabolism.2006,91:3891-3896.
(6)Knutzen R, Ezzat S. The cost of medical care for the acromegalic patient. Neuroendocrinology. 2006;83(3-4):139-44.
(7)Ingrid B, Ron D, et al. The'bio-assay'quality of life might be a better marker of disease activity in acromegalic patients than serum total IGF-I concentrations. European Journal of Endocrinology. 2005,152:217-224.
(8)S. M. Webb, L. Prieto, X. Badia, et al. Acromegaly Quality of Life Questionnaire(ACROQOL) a new health-related quality of life questionnaire for patients with acromegaly:development and psychometric properties.Clinical Endocrinology.2002,57:251-258.
(9)Xavier Badia, Susan M Webb, Luis Prieto et al. Acromegaly quality of life questionnaire (ACROQoL) Health and Quality Outcomes 2004,2:13-18.
(10)Susan M Webb, Xavier Badia, Nuria Lara Surinach. Validity and clinical applicability of the acromegaly quality of life questionnaire, ACROQoL:a 6-month prospective study. European Journal of Endocrinology.2006,155:269-277.
(11)Roman Trepp, Regula Evertst, Susan M. Webb, et al. Assessment of quality of life in patients with uncontrolled vs. controlled acromegaly using the Acromegaly Quality of-Life Questionnaire(ACROQoL). Clinical Endocrinology.2005,63:103-110.
(12)Rowles SV, Prieto L, Badia X, et al. Quality of life (QOL) in patients with acromegaly is severely impaired:use of a novel measure of QOL:acromegaly quality of life questionnaire. J Clin Endocrinol Metab.2005 Jun;90(6):3337-41
(13)Hua SC, Yan YH, Chang TC. Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly. Eur J Endocrinol.2006,155(6):831-7.
(14)杨樟卫陈盛新胡晋红健康相关生存质量的评估和卫生经济学。《药学实践杂志》1998,16：5-9。
(15)杨莉胡善联 卫生经济学评价中的健康结果测量中国药房2004,15：91-94.
(16)陈洁主编卫生经济学[M].第1版.北京：人民卫生出版社,2006：105-111.
(17)Angela N. Paisley, Susannah V. Rowles, Susan M. Webb, et al. Treatment of acromegaly improves quality of life, measured by ACROQoL. Clinical Endocrinology.2007,67:358-362.
(1)陈洁主编卫生经济学[M].第1版.北京：人民卫生出版社,2006：1-8.
(2)胡善联.卫生经济学概述[J].卫生经济研究1998,11(121)：42-44.
(3)中华医学会内分泌分会中华医学会神经外科分会.中国肢端肥大症诊治规范.
(4)G. Didoni, S. Grottoli, et al. cost-of-illness study of acromegaly patients in Italy[J]. J. Endocrinol. Invest.2004,27:1034-1039.
(5)David M, et al. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the diagnosis and treatment of acromegaly. Endocrine practice.2004,10:213-225.
(6)Sheppard MC. GH and mortality in acromegaly[J]. J Endocrinol Invest. 2005,28(11 Suppl International):75-7.
(7)史轶繁主编协和内分泌和代谢学[M].第一版.北京：科学出版社,1999：674-699.
(8)Erdinc Erturk, Ercan T, et al. Outcome of Surgery for Acromegaly Performed by Different Surgeons:Importance of Surgical Experience[J]. Pituitary 2005,8: 93-97.
(9)顾锋.肢端肥大症的内科治疗新进展[J].中国实用内科杂志.2006,26(22)：1777-1779.
(10)Zachary. B, Mary. V. Management of acromegaly:Is there a role for primary medical therapy? [J]. Rev Endocr Metab Disord.2008,9:83-94.
(11)Freda PU. Somatostatin analogs in acromegaly[J]. J Clin Endocrinol Metab.2002, 87(7):3013-8.
(12)Evelyn W, et al. Guideline on health economic evaluation (Austria). April 2006.
(13)蒯丽萍,张钧.卫生经济学的成本测算与分析[J].药学实践杂志2005,23(2)：124-127.
(14)胡善联.药物成本的研究[J].卫生经济研究.1999,5：45-47.
(15)Knutzen R, Ezzat S. The cost of medical care for the acromegalic patient[J]. Neuroendocrinology.2006;83(3-4):139-44.
(16)Wilson LS, Shin JL, Ezzat S. Longitudinal assessment of economic burden and clinical outcomes in acromegaly[J]. Endocr Pract.2001,7(3):170-80.
(17)Luque-Ramirez M, Paramo C, et al. Cost of management of invasive growth hormone-secreting macroadenoma[J]. J Endocrinol Invest.2007,30(7):541-5.
(18)吴久鸿,刘国恩.卫生经济学在我国的发展现状及应用前景[J].中国药物应用与监测.2005,1：1-4.
(19)何志高,陈洁,张丹.生命延长和健康改善的价值[J].药学实践杂志.1998,16(1)：1-5.
(20)J. Ayuk, R. N. Clayton, et al. Growth Hormone and Pituitary Radiotherapy, But Not Serum Insulin-Like Growth Factor-I Concentrations, Predict Excess Mortality in Patients with Acromegaly [J]. The Journal of Clinical Endocrinology & Metabolism.2004,89(4):1613-1617.
(21)Nienke B, Friedo D, et al. Determinants of Survival in Treated Acromegaly in a Single Center:Predictive Value of Serial Insulin-Like Growth Factor I Measurements[J]. The Journal of Clinical Endocrinology & Metabolism.2004, 89(6):2789-2796.
(22)Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol.2008,159(2):89-95.
(23)Rosario P, et al. Medical consequences of acromegaly:What are the effects of biochemical control?[J] Rev Endocr Metab Disord.2008,9:21-31.
(24)Andrea G, Ariel B, et al. Criteria for Cure of Acromegaly:A Consensus Statement J]. The Journal of Clinical Endocrinology & Metabolism.2000,85 No.2:526-529.
(25)Uberti EC, Bondanelli M, Ambrosio MR, Zatelli MC. Review of Cortina criteria for the diagnosis of acromegaly[J]. J Endocrinol Invest.2005,28(11 Suppl International):70-2.
(26)Ingrid B, Ron D, et al. The'bio-assay'quality of life might be a better marker of disease activity in acromegalic patients than serum total IGF-I concentrations [J]. European Journal of Endocrinology.2005,152:217-224.
(27)Sonino N, Scarpa E, Paoletta A, Fallo F, Boscaro M. Slow-release lanreotide treatment in acromegaly:effects on quality of life[J]. Psychother Psychosom. 1999,68(3):165-7.
(28)胡善联.药物效益的研究[J].卫生经济研究1999,7：40-41.
(29)何志高,陈洁卫生经济学及其在药品费用控制中的作用[J].中华医院管理杂 志.1999,15(5)：290-293.
(30)Li JK, Chow CC, et al. Treatment of Chinese acromegaly with a combination of bromocriptine and octreotide[J]. Aust N Z J Med.2000,30(4):457-61.
(31)David Moore, Catherine Meads. The Effectiveness and Cost-effectiveness of Somatostatin Analogues in the Treatment of Acromegaly. Produced by:The Aggressive Research Intelligence Facility (ARIF) &The West Midlands Development and Evaluation Service, Department of Public Health, University of Birmingham, UK.
(32)曹燕.决策分析模型在卫生经济学中的应用[J].中国药房200718(8)：561-563.
(33)Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics.1998,13(4):397-409.
(34)王倩.应用Markov模型进行临床决策分析[J].国外医学卫生经济分册.2000,17(2)：88-90.
(35)Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary,1999,2(1):29-41
